Efficacy of colistin versus β-lactams, aminoglycosides, rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1946-1952

  Montero, A ^a   Ariza, J ^a   Corbella, X ^a   Domenech A ^a   Cabellos, C ^a   Ayats, J ^a   Tubau, F ^a   Ardanuy, C ^a   Gudiol, F ^a  

^a N S Desamparados   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; IMIPENEM; RIFAMPICIN; SULBACTAM; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER; ACINETOBACTER INFECTIONS; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MICROBIAL; FEMALE; LUNG; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; RIFAMPIN; SURVIVAL ANALYSIS;

EID: 0036093514     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1946-1952.2002     Document Type: Article

References (45)

1. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii
2. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak
3. Epidemiological characterization of hospital-acquired Acinetobacter baumannii isolates from a 1500-bed teaching hospital by phenotypic and genotypic methods
4. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features
5. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases
6. A reassessment of the in-vitro activity of colistin sulphomethate sodium
7. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii
8. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
9. Activity of gentamicin, tobramycin, polymixin B, and colistimethate in mouse protection tests with Pseudomonas aeruginosa
10. Effects of aging on antibacterial mechanisms in experimental pneumonia
11. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria
12. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay
13. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium
14. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients
15. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
16. Acinetobacter species as nosocomial pathogens
17. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam
18. High-performance liquid chromatographic assay of sulbactam using pre-column reaction with 1,2,4-triazole
19. National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986-April 1996, issued May 1996
20. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium
21. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem
22. In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia
23. Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network
24. Polymyxins
25. Rifampicin (rifampin)
26. Binding of polymyxin antibiotics to tissues: The major determinant of distribution and persistence in the body
27. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii
28. An outbreak of multiresistant Acinetobacter baumannii in a university hospital in Sao Paulo, Brazil
29. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
30. Outbreak caused by two multiresistant Acinetobacter baumannii clones in a burns unit: Emergence of resistance to imipenem
31. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: Citywide prevalence, interinstitutional spread, and relation to antibiotic usage
32. In vitro and in vivo activities of antimicrobial agents against Acinetobacter calcoaceticus
33. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia
34. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains
35. Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period
36. Antimicrobial susceptibility of Acinetobacter species
37. Automated high-performance liquid chromatographic method for the determination of rifampicin in plasma
38. Detection of carbapenemase-producing Acinetobacter baumannii in a hospital
39. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods
40. Clinical importance and antibiotic resistance of Acinetobacter spp.
41. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii
42. In vivo efficacies of combinations of β-lactams, β-lactamase inhibitors and rifampin against Acinetobacter baumannii in a mouse pneumonia model